Pacritinib in Participants With Metastatic Castrate-Resistant Prostate Cancer That Progressed on or After Prior Treatment With Androgen Receptor Signaling Inhibitors
Part of paid clinical trials in Milwaukee, Wisconsin.
- Sponsor
- Medical College of Wisconsin
- Study ID
- NCT07226713
- Phase
- PHASE2
- Status
- Not Yet Recruiting
Notify me when recruiting opens
Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.
Add your contact details and location so we can keep your interest tied to this study.
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Pacritinib — DRUGPacritinib is an oral drug which will be taken daily at a dose of 200 mg twice a day (BID).
Study Details
This is a single-arm, open-label phase 2 study to evaluate the role of pacritinib for patients with metastatic castrate-resistant prostate cancer that have progressed on ARSI. Patients will receive pacritinib 200 mg twice daily. To be eligible, patients must have a biopsy of a metastatic site within 30 days of treatment that demonstrates positive STAT5 activation status
Key Dates
- Start date
- Jul 1, 2026
- Status verified
- Apr 2026
- Primary completion
- Mar 1, 2029
- Completion
- Mar 1, 2031
Study Design
- Enrollment
- 32 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: PacritinibPacritinib is an oral drug.
Primary Outcome Measure
Progression-free Survival [ Time Frame: Six months ]
Central Contacts
- Medical College of Wisconsin Cancer Center Clinical Trials Office866-680-0505
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Froedtert & the Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | Deepak Kilari, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Milwaukee, WI
By condition
By specialty
By research site
Related Studies
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical StudyPHASE2 · Recruiting · Astellas Pharma Global Development, Inc. · Anchorage, Alaska
- International Registry for Men With Advanced Prostate Cancer (IRONMAN)Recruiting · Prostate Cancer Clinical Trials Consortium · Birmingham, Alabama
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac StudyRecruiting · UMC Utrecht · Pittsburgh, Pennsylvania